83 results on '"Slater, O."'
Search Results
2. Assessing the health-fitness dynamics of endangered mountain caribou and the influence of maternal penning.
- Author
-
Lamb, Clayton T., Dubman, E., McNay, R.S., Giguere, L., Majchrzak, Y., Thacker, C., Slater, O., Macbeth, B., Owens-Beek, N., Muir, B., and Ford, A.T.
- Abstract
The health of wildlife plays a crucial role in population demography by connecting habitat and physiology. Southern mountain caribou, a population of woodland caribou (Rangifer tarandus caribou (Gmelin, 1978)) found in the mountains of southwest Canada, are facing significant threats. We evaluated the health of the Klinse-Za subpopulation within the central group of southern mountain caribou, which is part of an Indigenous-led conservation initiative aimed at enhancing caribou population growth through seasonal maternal penning. We collected health metrics from 46 female Klinse-Za caribou between 2014 and 2021. The health metrics included trace minerals, cortisol, biomarkers for inflammation, and pathogen prevalence. We compared these health metrics between penned and non-penned animals, reproductive and non-reproductive females, and nearby subpopulations. We provide correlative evidence linking reproductive success to trace nutrients but find no evidence for relationships with stress, exposure to pathogens, or biomarkers of inflammation. Based on the health metrics considered, Klinse-Za caribou were generally healthy relative to neighboring subpopulations and repeat capture for penning did not appear to create accumulated health issues. Penned caribou had lower fecal cortisol levels and inflammation markers compared to free-ranging animals. This work provides a baseline assessment of southern mountain caribou health and provides guidance on maternal penning activities in support of caribou recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Establishment of a UK national referral service for paediatric brachytherapy
- Author
-
Gaze, M., primary, Smeulders, N., additional, Sands, G., additional, Sullivan, T., additional, Bal, N., additional, Gill, E., additional, Peet, C., additional, Slater, O., additional, Rees, H., additional, Nguyen, T., additional, Humphries, P., additional, Pendse, D., additional, Allen, C., additional, Polhill, S., additional, Ackwerh, R., additional, Lim, P., additional, Eminowicz, G., additional, and Hoskin, P., additional
- Published
- 2022
- Full Text
- View/download PDF
4. A National Referral Service for Paediatric Brachytherapy: An Evolving Practice and Outcomes Over 13 Years
- Author
-
Gaze, M.N., primary, Smeulders, N., additional, Ackwerh, R., additional, Allen, C., additional, Bal, N., additional, Boutros, M., additional, Cho, A., additional, Eminowicz, G., additional, Gill, E., additional, Fittall, M.W., additional, Humphries, P.D., additional, Lim, P., additional, Mushtaq, I., additional, Nguyen, T., additional, Peet, C., additional, Pendse, D., additional, Polhill, S., additional, Rees, H., additional, Sands, G., additional, Shankar, A., additional, Slater, O., additional, Sullivan, T., additional, and Hoskin, P.J., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Correction to: Magnetic resonance features and cranial nerve involvement in pediatric head and neck rhabdomyosarcomas (Neuroradiology, (2021), 63, 11, (1925-1934), 10.1007/s00234-021-02765-0)
- Author
-
Talenti G., Picariello S., Robson C., Mertiri L., Russo C., Slater O., Bisdas S., Abate M. E., Perrotta S., Hewitt R., Mankad K., D'Arco F., Talenti, G., Picariello, S., Robson, C., Mertiri, L., Russo, C., Slater, O., Bisdas, S., Abate, M. E., Perrotta, S., Hewitt, R., Mankad, K., and D'Arco, F.
- Abstract
Originally, the article has been published online with inverted author names. This has been corrected above. The original article has been corrected.
- Published
- 2021
6. BLADDER FUNCTION AFTER CONSERVATIVE SURGERY AND HIGH-DOSE-RATE BRACHYTHERAPY FOR BLADDER-PROSTATE RHABDOMYOSARCOMA
- Author
-
Gaze M, Cho A, Hoskin P, Sands G, Sullivan T, Eminowicz G, Smeulders N, Slater O, and Lobo S
- Subjects
Prostate Rhabdomyosarcoma ,medicine.medical_specialty ,Text mining ,business.industry ,medicine ,Radiology ,business ,Bladder function ,High-Dose Rate Brachytherapy - Abstract
Background: Conservative-surgery (CS) brachytherapy (BT) techniques for local therapy in bladder-prostate rhabdomyosarcoma (BP-RMS) seeks to retain organ function. We report bladder function after high-dose-rate (HDR) BT combined with targeted CS for any vesical component of BP-RMS. Procedure: Prospective cohort of all BP-RMS patients between 2014-19 receiving HDR-BT (Iridium-192, 27.5Gy in 5 fractions) with/without percutaneous endoscopic-polypectomy (PEP) or partial cystectomy (PC). Functional assessment included frequency-volume-chart, voided volumes, post-void residual, flow studies, continence status and ultrasound scanning; abnormalities triggered video-urodynamics. Results: Thirteen patients (10 male), aged 9 months to 4 years (median 23 months), presented with localised fusion-negative embryonal BP-RMS measuring 23-140mm (median 43mm) in cranio-caudal extent. After induction chemotherapy, local treatment consisted of PC+BT in three, PEP+BT in four and BT alone in six. At a median 3½ years (range 1¾-7 years) follow up, all were alive without relapse. At a median age of 6 years (4-9 years), the median bladder capacity was 86% (47%-144%) of that expected for age, including 75% (74-114%) after PC. There was no relation to radiation dose to the bladder. Complications occurred in two: one urethral stricture and one vesical decompensation in a patient with pre-existing high-grade VUR. The remaining patients are dry by day; five with anticholinergic medication for urinary urgency. Three patients are enuretic. Conclusions: Day-time dryness at a median 3½ years after CS-HDR-BT was achieved in 92%, with 85% voiding urethrally, and 62% attaining day-and-night continence aged 4-9 years. We report reduced open surgery, with minimally-invasive percutaneous surgery with HDR-BT or brachytherapy alone being suitable for many.
- Published
- 2021
7. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study
- Author
-
Schoot, R. A., Theunissen, E. A.R., Slater, O., Lopez-Yurda, M., Zuur, C. L., Gaze, M. N., Chang, Y.-C., Mandeville, H. C., Gains, J. E., Rajput, K., Pieters, B. R., Fajardo, R. Davila, Talwar, R., Caron, H. N., Balm, A. J.M., Dreschler, W. A., and Merks, J. H.M.
- Published
- 2016
- Full Text
- View/download PDF
8. Facial deformations in patients treated for head and neck rhabdomyosarcoma, the difference between treatment modalities and a dose-effect relation for specific facial bones
- Author
-
Hol, M., primary, Suttie, M., additional, Hammond, P., additional, Slater, O., additional, Mandeville, H., additional, Gaze, M., additional, Chisholm, J., additional, Pieters, B., additional, Pazira, H., additional, Wiersma, J., additional, Merks, H., additional, Davila, R., additional, Becking, A., additional, and Smeele, L., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Melanotic neuroectodermal tumour of infancy: Refining the surgical approach
- Author
-
Rickart, A.J., primary, Drummond-Hay, V., additional, Suchak, A., additional, Sadiq, Z., additional, Sebire, N.J., additional, Slater, O., additional, and Mills, C., additional
- Published
- 2019
- Full Text
- View/download PDF
10. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion
- Author
-
Amrolia, PJ, Rao, K, Slater, O, Ramsay, A, Veys, PA, and Webb, DKH
- Published
- 2001
- Full Text
- View/download PDF
11. Effets indésirables cutanés du vémurafénib dans la cohorte européenne d’enfants traités pour histiocytose langerhansienne réfractaire mutée B-RAF (V600E)
- Author
-
Tardieu, M., primary, Néron, A., additional, Duvert-Lehembre, S., additional, Larbi, I.A., additional, Visser, J., additional, Hutter, C., additional, Sieni, E., additional, Kabbara, N., additional, Barkaoui, M., additional, Milne, P., additional, Haroche, J., additional, Hélias-Rodzewicz, Z., additional, Jehanne, M., additional, Kolenova, S., additional, Pagnier, A., additional, Templier, I., additional, Charles, J., additional, Leccia, M.-T., additional, Plat, G., additional, Lutun, A., additional, Heisig, A., additional, Ferster, A., additional, Efremova, V., additional, Blanc, L., additional, Nicholson, J., additional, Lambilliote, A., additional, Lissat, A., additional, Svojgr, K., additional, Bernard, F., additional, Aladjidi, N., additional, Marie-Cardine, A., additional, Idbaih, A., additional, Slater, O., additional, Minkov, M., additional, Taly, V., additional, Collin, M., additional, Alvarez, J.-C., additional, Emile, J.-F., additional, Héritier, S., additional, and Donadieu, J., additional
- Published
- 2018
- Full Text
- View/download PDF
12. Differences in Treatment-Induced Facial Growth Deformity Between AMORE and EBRT for Orbital Rhabdomyosarcoma Treatment in Children
- Author
-
Hol, M.L.F., primary, Maal, T.J.M., additional, Becking, A.G., additional, Pieters, B.R., additional, Mandeville, H.C., additional, Gaze, M.N., additional, Chisholm, J.C., additional, Slater, O., additional, Merks, J.H.M., additional, Saeed, P., additional, Alderliesten, T., additional, and Smeele, L.E., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Melanoma in congenital melanocytic naevi
- Author
-
Kinsler, V.A., primary, O'Hare, P., additional, Bulstrode, N., additional, Calonje, J.E., additional, Chong, W.K., additional, Hargrave, D., additional, Jacques, T., additional, Lomas, D., additional, Sebire, N.J., additional, and Slater, O., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma
- Author
-
Clement, S.C., primary, Schoot, R.A., additional, Slater, O., additional, Chisholm, J.C., additional, Abela, C., additional, Balm, A.J.M., additional, van den Brekel, M.W., additional, Breunis, W.B., additional, Chang, Y.C., additional, Davila Fajardo, R., additional, Dunaway, D., additional, Gajdosova, E., additional, Gaze, M.N., additional, Gupta, S., additional, Hartley, B., additional, Kremer, L.C.M., additional, van Lennep, M., additional, Levitt, G.A., additional, Mandeville, H.C., additional, Pieters, B.R., additional, Saeed, P., additional, Smeele, L.E., additional, Strackee, S.D., additional, Ronckers, C.M., additional, Caron, H.N., additional, van Santen, H.M., additional, and Merks, J.H.M., additional
- Published
- 2016
- Full Text
- View/download PDF
15. 9411 The novel HSP90 inhibitor NVP-AUY922 demonstrates activity in rhabdomyosarcoma cell lines
- Author
-
Slater, O., primary, Renshaw, J., additional, Workman, P., additional, and Pritchard-Jones, K., additional
- Published
- 2009
- Full Text
- View/download PDF
16. Clinical relevance of molecular genetics to paediatric sarcomas
- Author
-
Slater, O., primary and Shipley, J., additional
- Published
- 2007
- Full Text
- View/download PDF
17. The influence of breakfast and a snack on psychological functioning
- Author
-
Benton, D., Slater, O., and Donohoe, R. T.
- Published
- 2001
- Full Text
- View/download PDF
18. Brachytherapy for rhabdomyosarcoma: Survey of international clinical practice and development of guidelines.
- Author
-
Dávila Fajardo R, Scarzello G, Gaze MN, Boterberg T, Cameron A, Fuchs J, Guérin F, Hoskin P, Krasin MJ, Kroon P, Magelssen H, Mercke C, Merks JHM, Paulsen F, Pommier P, Ramos M, Rees H, Rogers T, Schmid M, Seitz G, Slater O, Smeulders N, Stenman J, Terwisscha S, Chargari C, and Mandeville HC
- Subjects
- Humans, Child, Surveys and Questionnaires, Radiotherapy Dosage, Rhabdomyosarcoma radiotherapy, Brachytherapy methods, Brachytherapy standards, Practice Guidelines as Topic
- Abstract
Background and Purpose: The purpose of this study was to address the lack of published data on the use of brachytherapy in pediatric rhabdomyosarcoma by describing current practice as starting point to develop consensus guidelines., Materials and Methods: An international expert panel on the treatment of pediatric rhabdomyosarcoma comprising 24 (pediatric) radiation oncologists, brachytherapists and pediatric surgeons met for a Brachytherapy Workshop hosted by the European paediatric Soft tissue Sarcoma Study Group (EpSSG). The panel's clinical experience, the results of a previously distributed questionnaire, and a review of the literature were presented., Results: The survey indicated the most common use of brachytherapy to be in combination with tumor resection, followed by brachytherapy as sole local therapy modality. HDR was increasingly deployed in pediatric practice, especially for genitourinary sites. Brachytherapy planning was mostly by 3D imaging based on CT. Recommendations for patient selection, treatment requirements, implant technique, delineation, dose prescription, dose reporting and clinical management were defined., Conclusions: Consensus guidelines for the use of brachytherapy in pediatric rhabdomyosarcoma have been developed through multicenter collaboration establishing the basis for future work. These have been adopted for the open EpSSG overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS)., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflicts of interest Dr. Mark N. Gaze is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and by the Radiation Research Unit at the Cancer Research UK City of London Centre Award [C7893/A28990]. Prof. Dr. Peter Hoskin is supported by the NIHR Manchester Biomedical Centre. Dr. Henry C. Mandeville is supported by the National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Facial deformation following treatment for pediatric head and neck rhabdomyosarcoma; the difference between treatment modalities. Results of a trans-Atlantic, multicenter cross-sectional cohort study.
- Author
-
Hol MLF, Indelicato DJ, Slater O, Kolb F, Hewitt RJ, Ong J, Becking AG, Gains J, Bradley J, Sandler E, Gaze MN, Pieters B, Mandeville H, Fajardo RD, Schoot R, Merks JHM, Hammond P, Smeele LE, and Suttie M
- Subjects
- Child, Humans, Infant, Cross-Sectional Studies, Cohort Studies, Combined Modality Therapy, Head and Neck Neoplasms radiotherapy, Rhabdomyosarcoma, Embryonal, Rhabdomyosarcoma radiotherapy, Rhabdomyosarcoma pathology
- Abstract
Background: The four different local therapy strategies used for head and neck rhabdomyosarcoma (HNRMS) include proton therapy (PT), photon therapy (RT), surgery with radiotherapy (Paris-method), and surgery with brachytherapy (AMORE). Local control and survival is comparable; however, the impact of these different treatments on facial deformation is still poorly understood. This study aims to quantify facial deformation and investigates the differences in facial deformation between treatment modalities., Methods: Across four European and North American institutions, HNRMS survivors treated between 1990 and 2017, more than 2 years post treatment, had a 3D photograph taken. Using dense surface modeling, we computed facial signatures for each survivor to show facial deformation relative to 35 age-sex-ethnicity-matched controls. Additionally, we computed individual facial asymmetry., Findings: A total of 173 HNRMS survivors were included, survivors showed significantly reduced facial growth (p < .001) compared to healthy controls. Partitioned by tumor site, there was reduced facial growth in survivors with nonparameningeal primaries (p = .002), and parameningeal primaries (p ≤.001), but not for orbital primaries (p = .080) All patients were significantly more asymmetric than healthy controls, independent of treatment modality (p ≤ .001). There was significantly more facial deformation in orbital patients when comparing RT to AMORE (p = .046). In survivors with a parameningeal tumor, there was significantly less facial deformation in PT when compared to RT (p = .009) and Paris-method (p = .007)., Interpretation: When selecting optimal treatment, musculoskeletal facial outcomes are an expected difference between treatment options. These anticipated differences are currently based on clinicians' bias, expertise, and experience. These data supplement clinician judgment with an objective analysis highlighting the impact of patient age and tumor site between existing treatment options., (© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
20. Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.
- Author
-
Milne P, Bomken S, Slater O, Kumar A, Nelson A, Roy S, Velazquez J, Mankad K, Nicholson J, Yeomanson D, Grundy R, Kamal A, Penn A, Pears J, Millen G, Morland B, Hayden J, Lam J, Madkhali M, MacDonald J, Singh P, Pagan S, Rodriguez-Galindo C, Minkov M, Donadieu J, Picarsic J, Allen C, Bigley V, and Collin M
- Subjects
- Humans, Leukocytes, Mononuclear, Mutation, Male, Female, Infant, Child, Preschool, Cell Lineage genetics, Dendritic Cells pathology, Histiocytosis, Langerhans-Cell genetics, Histiocytosis, Langerhans-Cell pathology, Monocytes pathology, T-Lymphocytes pathology
- Abstract
Most children with high-risk Langerhans cell histiocytosis (LCH) have BRAFV600E mutation. BRAFV600E alleles are detectable in myeloid mononuclear cells at diagnosis but it is not known if the cellular distribution of mutation evolves over time. Here, the profiles of 16 patients with high-risk disease were analyzed. Two received conventional salvage chemotherapy, 4 patients on inhibitors were tracked at intervals of 3 to 6 years, and 10 patients, also given inhibitors, were analyzed more than 2 years after diagnosis. In contrast to the patients responding to salvage chemotherapy who completely cleared BRAFV600E within 6 months, children who received inhibitors maintained high BRAFV600E alleles in their blood. At diagnosis, mutation was detected predominantly in monocytes and myeloid dendritic cells. With time, mutation switched to the T-cell compartment, which accounted for most of the mutational burden in peripheral blood mononuclear cells, more than 2 years from diagnosis (median, 85.4%; range, 44.5%-100%). The highest level of mutation occurred in naïve CD4+ T cells (median, 51.2%; range, 3.8%-93.5%). This study reveals an unexpected lineage switch of BRAFV600E mutation in high-risk LCH, which may influence monitoring strategies for the potential withdrawal of inhibitor treatment and has new implications for the pathogenesis of neurodegeneration, which occurred in 4 patients., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
21. Impact of molecular biology in children with ALK+ inflammatory myofibroblastic tumour. A reflexion from a case report.
- Author
-
Aguirregomezcorta FR, Hedge K, Slater O, Benito AI, and Jorgensen M
- Subjects
- Humans, Child, Molecular Biology, Receptor Protein-Tyrosine Kinases, Neoplasms
- Published
- 2023
- Full Text
- View/download PDF
22. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes.
- Author
-
Green K, Panagopoulou P, D'Arco F, O'Hare P, Bowman R, Walters B, Dahl C, Jorgensen M, Patel P, Slater O, Ahmed R, Bailey S, Carceller F, Collins R, Corley E, English M, Howells L, Kamal A, Kilday JJ, Lowis S, Lumb B, Pace E, Picton S, Pizer B, Shafiq A, Uzunova L, Wayman H, Wilson S, Hargrave D, and Opocher E
- Subjects
- Child, Humans, Bevacizumab therapeutic use, Irinotecan, Visual Acuity, United Kingdom, Optic Nerve Glioma drug therapy
- Abstract
Background: Bevacizumab is increasingly used in children with pediatric low-grade glioma (PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to provide larger cohort "real life" safety and efficacy data including functional visual outcomes., Methods: Children receiving bevacizumab-based treatments (BBT) for PLGG (2009-2020) from 11 centers were included. Standardized neuro-radiological (RANO-LGG) and visual (logMAR visual acuity) criteria were used to assess clinical-radiological correlation, survival outcomes and multivariate prognostic analysis., Results: Eighty-eight children with PLGG received BBT either as 3rd line with irinotecan (85%) or alongside 1st/2nd line chemotherapies (15%). Toxicity was limited and minimal. Partial response (PR, 40%), stable disease (SD, 49%), and progressive disease (PD, 11%) were seen during BBT. However, 65% progressed at 8 months (median) from BBT cessation, leading to a radiology-based 3 yr-progression-free survival (PFS) of 29%. Diencephalic syndrome (P = .03) was associated with adverse PFS. Pre-existing visual morbidity included unilateral (25%) or bilateral (11%) blindness. Improvement (29%) or stabilization (49%) of visual acuity was achieved, more often in patients' best eyes. Vision deteriorated during BBT in 14 (22%), with 3-year visual-PFS of 53%; more often in patients' worst eyes. A superior visual outcome (P = .023) was seen in neurofibromatosis type 1-associated optic pathway glioma (OPG). Concordance between visual and radiological responses was 36%; optimized to 48% using only best eye responses., Conclusions: BBTs provide effective short-term PLGG control and delay further progression, with a better sustained visual (best > worst eye) than radiological response. Further research could optimize the role of BBT toward a potentially sight-saving strategy in OPG., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
23. Patient-reported outcomes in childhood head and neck rhabdomyosarcoma survivors and their relation to physician-graded adverse events-A multicenter study using the FACE-Q Craniofacial module.
- Author
-
Morfouace M, Hol MLF, Schoot RA, Slater O, Indelicato DJ, Kolb F, Smeele LE, Merks JHM, Rae C, Maurice-Stam H, Klassen AF, and Grootenhuis MA
- Subjects
- Child, Humans, Adolescent, Young Adult, Adult, Cross-Sectional Studies, Quality of Life, Survivors, Patient Reported Outcome Measures, Rhabdomyosarcoma, Embryonal, Rhabdomyosarcoma therapy, Physicians
- Abstract
Introduction: Adverse events (AE) of treatment are prevalent and diverse in head and neck rhabdomyosarcoma (HNRMS) survivors. These AEs are often reported by physicians; however, patients' perceptions of specific AE are not well known. In this study, we explored patient-reported outcomes measuring appearance, health-related quality of life (HRQOL), and facial function in HNRMS survivors. Second, we assess the relationship between physician grading of AE and patient reporting., Materials and Methods: Survivors of pediatric HNRMS, diagnosed between 1993 and 2017, who were at least 2 years after completing treatment were invited to an outpatient clinic as part of a multicenter cross-sectional cohort study. At the outpatient clinics, survivors aged ≥8 years filled out the FACE-Q Craniofacial module; a patient-reported outcome instrument measuring issues specific to patients with facial differences. AE were systematically assessed by a multidisciplinary team based on the Common Terminology Criteria of Adverse Events system., Results: Seventy-seven survivors with a median age of 16 years (range 8-43) and median follow-up of 10 years (range 2-42) completed the questionnaire and were screened for AEs. Patient-reported outcomes varied widely between survivors. Many survivors reported negative consequences: 82% on appearance items, 81% on HRQOL items, and 38% on facial function items. There was a weak correlation between physician-scored AEs and the majority of patient-reported outcomes specific for those AEs., Conclusions: Physician-graded AEs are not sufficient to provide tailored care for HNMRS survivors. Findings from this study highlight the importance of incorporating patient-reported outcome measures in survivorship follow-up., (© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
24. Developments in the Surgical Approach to Staging and Resection of Rhabdomyosarcoma.
- Author
-
Terwisscha van Scheltinga S, Rogers T, Smeulders N, deCorti F, Guerin F, Craigie R, Burrieza GG, Smeele L, Hol M, van Rijn R, Fuchs J, Seitz G, Schmidt A, Timmermann B, Tunn PU, Chargari C, Dávila Fajardo R, Slater O, Gains J, and Merks H
- Abstract
Although survival after rhabdosarcoma treatment has improved over the years, one third of patients still develop locoregional relapse. This review aims to highlight developments pertaining to staging and local treatment of specific RMS tumor sites, including head and neck, chest/trunk, bladder-prostate, female genito-urinary, perianal, and extremity sites.
- Published
- 2023
- Full Text
- View/download PDF
25. Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma.
- Author
-
Lobo S, Gaze MN, Slater O, Hoskin P, Sands G, Sullivan T, Cho A, Eminowicz G, and Smeulders N
- Subjects
- Child, Humans, Male, Neoplasm Recurrence, Local, Prospective Studies, Prostate, Radiotherapy Dosage, Urinary Bladder, Brachytherapy adverse effects, Brachytherapy methods, Pelvic Neoplasms, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery, Rhabdomyosarcoma radiotherapy, Rhabdomyosarcoma surgery, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms radiotherapy, Urinary Bladder Neoplasms surgery
- Abstract
Background: Conservative surgery (CS) brachytherapy (BT) techniques for local therapy in bladder-prostate rhabdomyosarcoma (BP-RMS) seek to retain organ function. We report bladder function after high-dose rate (HDR) BT combined with targeted CS for any vesical component of BP-RMS., Procedure: Prospective cohort of all BP-RMS patients between 2014 and 2019 receiving HDR-BT (iridium-192, 27.5 Gy in five fractions) with/without percutaneous endoscopic polypectomy (PEP) or partial cystectomy (PC). Functional assessment included frequency-volume chart, voided volumes, post-void residual, flow studies, continence status and ultrasound scanning; abnormalities triggered video urodynamics., Results: Thirteen patients (10 male), aged 9 months to 4 years (median 23 months), presented with localised fusion-negative embryonal BP-RMS measuring 23-140 mm (median 43 mm) in cranio-caudal extent. After induction chemotherapy, local treatment consisted of PC+BT in three, PEP+BT in four and BT alone in six. At a median 3.5 years (range 21 months to 7 years) follow-up, all were alive without relapse. At a median age of 6 years (4-9 years), the median bladder capacity was 86% (47%-144%) of that expected for age, including 75% (74%-114%) after PC. Radiation dose to the bladder was associated with urinary urgency, but not bladder capacity or nocturnal enuresis. Complications occurred in two: one urethral stricture and one vesical decompensation in a patient with pre-existing high-grade vesico-ureteric reflux (VUR). The remaining patients were dry by day; five with anticholinergic medication for urinary urgency. Three patients are enuretic., Conclusions: Day-time dryness at a median 3.5 years after CS-HDR-BT was achieved in 92%, with 85% voiding urethrally, and 62% attaining day-and-night continence aged 4-9 years. We report reduced open surgery with minimally invasive percutaneous surgery, with HDR-BT or BT alone being suitable for many., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
26. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
- Author
-
Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, and Veal GJ
- Subjects
- Child, Drug Monitoring, Humans, Infant, Infant, Newborn, Vinblastine, Myofibroma drug therapy, Myofibromatosis
- Abstract
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations., (© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
27. Development of a Simple and Effective Lipid-A Antagonist Based on Computational Prediction.
- Author
-
Slater O, Dhami KB, Shrestha G, Kontoyianni M, Nichols MR, and Demchenko AV
- Subjects
- Binding Sites, Humans, Inflammation, Toll-Like Receptor 4 chemistry, Toll-Like Receptor 4 metabolism, Lipid A chemistry, Lipopolysaccharides chemistry
- Abstract
Sepsis is a serious medical condition characterized by bacterial infection and a subsequent massive systemic inflammatory response. In an effort to identify compounds that block lipopolysaccharide (LPS)-induced inflammation reported herein is the development of simple Lipid-A analogues that lack a disaccharide core yet still possess potent antagonistic activity against LPS. The structure of the new lead compound was developed based on predictive computational experiments. LPS antagonism by the lead compound was not straightforward, and a biphasic effect was observed suggesting a possibility of more than one binding site. An IC
50 value of 13 nM for the new compound was determined for the possible high affinity site. The combination of computational, synthetic, and biological studies revealed new structural determinants of these simplified analogues. It is expected that the acquired information will aid future design of LPS targeting glycopharmaceuticals.- Published
- 2022
- Full Text
- View/download PDF
28. Extracorporeal membrane oxygenation: Bridging therapy in paediatric pulmonary Langerhans cell histiocytosis.
- Author
-
Bhatt R, Semple T, Slater O, Nicholson AG, Casanueva L, Desai A, Hoschtitzky A, Milne P, and Langley R
- Subjects
- Child, Humans, Cardiopulmonary Resuscitation, Extracorporeal Membrane Oxygenation, Histiocytosis, Langerhans-Cell therapy
- Published
- 2022
- Full Text
- View/download PDF
29. Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group.
- Author
-
Bisogno G, Minard-Colin V, Arush MB, Daragjati J, Coppadoro B, Gallego S, Alaggio R, Smeulders N, Mudry P, Zin A, Merks JHM, and Slater O
- Subjects
- Child, Gene Fusion, Humans, Progression-Free Survival, Repressor Proteins, Trans-Activators, Rhabdomyosarcoma pathology, Rhabdomyosarcoma, Embryonal
- Abstract
Procedure: Congenital rhabdomyosarcoma (RMS) represents a challenging disease due to its characteristics and the difficulties in delivering treatment in this immature population., Methods: We analyzed treatment and outcome of patients with congenital RMS, defined as tumor diagnosed in the first 2 months of life, enrolled in the European paediatric Soft tissue sarcoma Study Group protocols., Results: Twenty-four patients with congenital RMS were registered. All, except one patient (PAX3-FOXO1-positive metastatic RMS), had favorable histology and localized disease. Three patients had VGLL2-CITED2/NCOA2 fusion. Complete tumor resection was achieved in 10 patients. No radiotherapy was given. Chemotherapy doses were adjusted to age and weight. Only two patients required further dose reduction for toxicity. The 5-year event-free survival (EFS) and overall survival (OS) were 75.0% (95% confidence interval [CI] 52.6-87.9) and 87.3% (95% CI 65.6-95.7), respectively. Progressive disease was the main cause of treatment failure., Conclusion: Patients with congenital RMS presented with a favorable disease, allowing weight- and age-adjusted doses of chemotherapy and avoidance of irradiation, without compromising the outcome., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
30. Localised rhabdomyosarcoma in infants (<12 months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 study.
- Author
-
Slater O, Gains JE, Kelsey AM, De Corti F, Zanetti I, Coppadoro B, Jorgensen M, Gallego S, Orbach DH, Glosli H, Cesen M, Gaze MN, Smeulders N, Ferrari A, Jenney M, Minard-Colin V, Bisogno G, and Merks JHM
- Subjects
- Child, Preschool, Female, History, 21st Century, Humans, Infant, Infant, Newborn, Male, Rhabdomyosarcoma drug therapy
- Abstract
Background: Infants (<12 months) with rhabdomyosarcoma have historically had poorer outcome than the older age groups. We present outcomes for infants and young children aged 12-36 months with localised rhabdomyosarcoma with a particular emphasis on infants., Patients and Methods: All children less than 36 months of age enrolled on the EpSSG RMS 2005 study for localised disease are included. Treatment comprised chemotherapy, local surgery and/or radiation therapy adapted to risk group and age. Main outcome measures were event free survival (EFS) and overall survival (OS)., Results: Outcome data were available for 485/490 patients aged less than 36 months, 110 were infants. Infants received chemotherapy according to the risk group with no toxic deaths. Radiotherapy was delivered to 33.6% of infants and 63.5% of 12-36 months old, with respectively 41.7% and 22.2% receiving brachytherapy. Radical surgery was performed in 62% of infants and 57.1% of 12-36 months old. Median follow up for patients who are alive (n = 393) was 72.7 months (range 6.9-158.2). Five-year OS for infants was 88.4% (95%CI 80.3-93.2), which is significantly better than the OS in 12-36 months old patients of 78.0% (95%CI 73.2-82.0; p = 0.0204). Five-year EFS for infants was 72.5% (95%CI 62.8-80.0) compared with 66.1% (95%CI 61.0-70.7; p = 0.2663) for 12-36 months old., Conclusion: Infants treated on RMS 2005 achieved excellent EFS and OS. The EpSSG RMS 2005 chemotherapy regimen, combined with an increase in the application of adequate local therapy, improvements in imaging and supportive care and potentially favourable patients' characteristics may have contributed to these results., Competing Interests: Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Magnetic resonance features and cranial nerve involvement in pediatric head and neck rhabdomyosarcomas.
- Author
-
Talenti G, Picariello S, Robson C, Mertiri L, Russo C, Slater O, Bisdas S, Abate ME, Perrotta S, Hewitt R, Mankad K, and D'Arco F
- Subjects
- Adult, Child, Cranial Nerves diagnostic imaging, Humans, Magnetic Resonance Spectroscopy, Retrospective Studies, Head and Neck Neoplasms diagnostic imaging, Rhabdomyosarcoma diagnostic imaging
- Abstract
Purpose: Rhabdomyosarcoma (RMS) is a malignant tumor frequent in children. The frequency and characteristics of cranial nerve involvement in pediatric head and neck (H&N) RMS have been scarcely reported. The aim of this study is to review a large cohort of pediatric head and neck RMS with an emphasis on cranial nerve involvement., Methods: We retrospectively reviewed H&N RMS cases from 3 tertiary hospitals over a 10-year period. Cranial nerve involvement was defined as radiologically apparent tumor extension along a nerve and/or the presence of secondary signs. Scans were reviewed by two pediatric neuroradiologists, blinded to clinical data., Results: A total of 52 patients met the inclusion criteria. Histologically, 39/52 were embryonal RMS, while 13/52 were alveolar RMS. Regional lymph nodes metastases were present in 19.2%. Cranial nerve involvement was present in 36.5%. Nerves were mainly involved as a direct extension of the mass through skull base foramina or after invasion of cavernous sinus, Meckel's cave, orbital apex, or stylomastoid foramen., Conclusion: Cranial nerve involvement is frequent in pediatric head and neck RMS and occurs secondary to "geographic" invasion due to direct extension through skull base foramina or cavernous sinus. These tumors never showed distant perineural metastatic disease as is seen in cases of adult head and neck carcinomas. This implies a different biological interaction between the nerves and these tumors in comparison to adult H&N tumors., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
32. Correction to: Magnetic resonance features and cranial nerve involvement in pediatric head and neck rhabdomyosarcomas.
- Author
-
Talenti G, Picariello S, Robson C, Mertiri L, Russo C, Slater O, Bisdas S, Abate ME, Perrotta S, Hewitt R, Mankad K, and D'Arco F
- Published
- 2021
- Full Text
- View/download PDF
33. Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.
- Author
-
Neumann WL, Sandoval KE, Mobayen S, Minaeian M, Kukielski SG, Srabony KN, Frare R, Slater O, Farr SA, Niehoff ML, Hospital A, Kontoyianni M, Crider AM, and Witt KA
- Abstract
Somatostatin receptor-4 (SST
4 ) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit ( 4 ) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki < 1 nM. These compounds showed >500-fold affinity for SST4 as compared to SST2A . SST4 activities were consistent with the respective SST4 binding affinities (EC50 < 10 nM for 34 compounds). Compound 208 (SST4 Ki = 0.7 nM; EC50 = 2.5 nM; >600-fold selectivity over SST2A ) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1 ) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1 ) and oral (0.01, 10 mg kg-1 ) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD., Competing Interests: The authors declared the following conflict of interests: Drs. Neumann, Sandoval, Kontoyianni, Hospital, Crider, and Witt are co-inventors on patent applications for the development of SST4 agonists, through Southern Illinois University Edwardsville (USA patent application No. PCT/US2018/032368; European National Application No. 18798793.8, Japanese Application No. 2019-562574). Ken Witt is CEO of Somatolynk Inc., a company focused on advancement of SST4 agonists., (This journal is © The Royal Society of Chemistry.)- Published
- 2021
- Full Text
- View/download PDF
34. Parents' responses to prognostic disclosure at diagnosis of a child with a high-risk brain tumor: Analysis of clinician-parent interactions and implications for clinical practice.
- Author
-
Bluebond-Langner M, Hall N, Vincent K, Henderson EM, Russell J, Beecham E, Bryan G, Gains JE, Gaze MN, Slater O, Langner RW, and Hargrave D
- Subjects
- Adolescent, Brain Neoplasms mortality, Brain Neoplasms therapy, Child, Child, Preschool, Female, Humans, Infant, Male, Prognosis, Surveys and Questionnaires, Survival Rate, Brain Neoplasms diagnosis, Communication, Parents psychology, Physician-Patient Relations, Practice Patterns, Physicians' standards, Referral and Consultation standards, Truth Disclosure ethics
- Abstract
Background: Previous studies have found that parents of children with cancer desire more prognostic information than is often given even when prognosis is poor. We explored in audio-recorded consultations the kinds of information they seek., Methods: Ethnographic study including observation and audio recording of consultations at diagnosis. Consultations were transcribed and analyzed using an interactionist perspective including tools drawn from conversation and discourse analysis., Results: Enrolled 21 parents and 12 clinicians in 13 cases of children diagnosed with a high-risk brain tumor (HRBT) over 20 months at a tertiary pediatric oncology center. Clinicians presented prognostic information in all cases. Through their questions, parents revealed what further information they desired. Clinicians made clear that no one could be absolutely certain what the future held for an individual child. Explicit communication about prognosis did not satisfy parents' desire for information about their own child. Parents tried to personalize prognostic information and to apply it to their own situation. Parents moved beyond prognostic information presented and drew conclusions, which could change over time. Parents who were present in the same consultations could form different views of their child's prognosis., Conclusion: Population level prognostic information left parents uncertain about their child's future. The need parents revealed was not for more such information but rather how to use the information given and how to apply it to their child in the face of such uncertainty. Further research is needed on how best to help parents deal with uncertainty and make prognostic information actionable., (© 2020 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
35. Comment on: "Tumour-agnostic drugs in paediatric cancers", Chisholm et al., BJC 2020.
- Author
-
Oliver TRW, Jackson TJ, Ogunbiyi O, Sebire N, Slater O, Jorgensen M, and Behjati S
- Subjects
- Child, Humans, Neoplasms drug therapy, Pharmaceutical Preparations
- Published
- 2021
- Full Text
- View/download PDF
36. Challenges in the Diagnosis of Medulloblastoma Recurrence at an Unusual Site in a Patient With Prader-Willi Syndrome.
- Author
-
Panagopoulou P, Sattar S, Aquilina K, Jan W, Jacques T, and Slater O
- Subjects
- Cerebellar Neoplasms etiology, Child, Female, Humans, Medulloblastoma etiology, Neoplasm Recurrence, Local etiology, Prognosis, Cerebellar Neoplasms diagnosis, Medulloblastoma diagnosis, Neoplasm Recurrence, Local diagnosis, Prader-Willi Syndrome complications
- Abstract
Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates range between 50% and 80% depending on histology and other biologic features, metastases, and treatment approach. Prader-Willi syndrome (PWS) is a genetically inherited disorder characterized by dysmorphic features, mental retardation, obesity, and hypogonadism among other features. We describe a 10.5-year-old girl with PWS and previous standard-risk medulloblastoma that relapsed in the pons 3 years after the end of treatment. Diagnosis of relapse was delayed by a preceding varicella infection, an initial clinical/radiologic response to steroids and the unusual location, and was confirmed with a stereotactic biopsy. Second-line therapy was commenced, however, the patient rapidly deteriorated and died. This is the first report of medulloblastoma in a patient with PWS.
- Published
- 2020
- Full Text
- View/download PDF
37. Decoding Protein-protein Interactions: An Overview.
- Author
-
Slater O, Miller B, and Kontoyianni M
- Subjects
- Amino Acid Sequence, Binding Sites, Computer-Aided Design, Databases, Protein, Drug Design, Humans, Hydrogen Bonding, Hydrophobic and Hydrophilic Interactions, Machine Learning, Molecular Docking Simulation, Protein Binding, Protein Conformation, Protein Interaction Mapping, Structure-Activity Relationship, Proteins chemistry
- Abstract
Drug discovery has focused on the paradigm "one drug, one target" for a long time. However, small molecules can act at multiple macromolecular targets, which serves as the basis for drug repurposing. In an effort to expand the target space, and given advances in X-ray crystallography, protein-protein interactions have become an emerging focus area of drug discovery enterprises. Proteins interact with other biomolecules and it is this intricate network of interactions that determines the behavior of the system and its biological processes. In this review, we briefly discuss networks in disease, followed by computational methods for protein-protein complex prediction. Computational methodologies and techniques employed towards objectives such as protein-protein docking, protein-protein interactions, and interface predictions are described extensively. Docking aims at producing a complex between proteins, while interface predictions identify a subset of residues on one protein that could interact with a partner, and protein-protein interaction sites address whether two proteins interact. In addition, approaches to predict hot spots and binding sites are presented along with a representative example of our internal project on the chemokine CXC receptor 3 B-isoform and predictive modeling with IP10 and PF4., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2020
- Full Text
- View/download PDF
38. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
- Author
-
Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, Kabbara N, Barkaoui M, Miron J, Chalard F, Milne P, Haroche J, Cohen F, Hélias-Rodzewicz Z, Simon N, Jehanne M, Kolenova A, Pagnier A, Aladjidi N, Schneider P, Plat G, Lutun A, Sonntagbauer A, Lehrnbecher T, Ferster A, Efremova V, Ahlmann M, Blanc L, Nicholson J, Lambilliote A, Boudiaf H, Lissat A, Svojgr K, Bernard F, Elitzur S, Golan M, Evseev D, Maschan M, Idbaih A, Slater O, Minkov M, Taly V, Collin M, Alvarez JC, Emile JF, and Héritier S
- Subjects
- Adolescent, Age Factors, Child, Child, Preschool, Drug Resistance, Europe, Female, Histiocytosis, Langerhans-Cell diagnosis, Histiocytosis, Langerhans-Cell genetics, Humans, Infant, Male, Mutation, Protein Kinase Inhibitors adverse effects, Proto-Oncogene Proteins B-raf genetics, Severity of Illness Index, Signal Transduction, Time Factors, Treatment Outcome, Vemurafenib adverse effects, Histiocytosis, Langerhans-Cell drug therapy, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Vemurafenib therapeutic use
- Abstract
Purpose: Off-label use of vemurafenib (VMF) to treat BRAF
V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated., Patients and Methods: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score., Results: LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to 0 ( P < .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) and was associated with a higher risk of reactivation at VMF discontinuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone., Conclusion: VMF seemed safe and effective in children with refractory BRAFV600E -positive LCH. Additional studies are needed to find effective maintenance therapy approaches.- Published
- 2019
- Full Text
- View/download PDF
39. European Echinococcus multilocularis Identified in Patients in Canada.
- Author
-
Massolo A, Klein C, Kowalewska-Grochowska K, Belga S, MacDonald C, Vaughan S, Girgis S, Giunchi D, Bramer SA, Santa MA, Grant DM, Mori K, Duignan P, Slater O, Gottstein B, Müller N, and Houston S
- Subjects
- Animals, Canada, Communicable Diseases, Emerging transmission, Disease Reservoirs, Echinococcosis transmission, Echinococcosis veterinary, Echinococcosis, Hepatic transmission, Echinococcus multilocularis isolation & purification, Humans, Phylogeny, Zoonoses, Communicable Diseases, Emerging parasitology, Echinococcosis parasitology, Echinococcosis, Hepatic parasitology, Echinococcus multilocularis genetics
- Published
- 2019
- Full Text
- View/download PDF
40. The compromise of virtual screening and its impact on drug discovery.
- Author
-
Slater O and Kontoyianni M
- Subjects
- Humans, Pharmaceutical Preparations chemistry, Research Design, Structure-Activity Relationship, Drug Design, Drug Discovery methods, Molecular Docking Simulation methods
- Abstract
Introduction : Docking and structure-based virtual screening (VS) have been standard approaches in structure-based design for over two decades. However, our understanding of the limitations, potential, and strength of these techniques has enhanced, raising expectations. Areas covered : Based on a survey of reports in the past five years, we assess whether VS: (1) predicts binding poses in agreement with crystallographic data (when available); (2) is a superior screening tool, as often claimed; (3) is successful in identifying chemical scaffolds that can be starting points for subsequent lead optimization cycles. Data shows that knowledge of the target and its chemotypes in postprocessing lead to viable hits in early drug discovery endeavors. Expert opinion : VS is capable of accurate placements in the pocket for the most part, but does not consistently score screening collections accurately. What matters is capitalization on available resources to get closer to a viable lead or optimizable series. Integration of approaches, subjective hit selection guided by knowledge of the receptor or endogenous ligand, libraries driven by experimental guides, validation studies to identify the best docking/scoring that reproduces experimental findings, constraints regarding receptor-ligand interactions, thoroughly designed methodologies, and predefined cutoff scoring criteria strengthen VS's position in pharmaceutical research.
- Published
- 2019
- Full Text
- View/download PDF
41. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma.
- Author
-
Vaarwerk B, Schoot RA, Maurice-Stam H, Slater O, Hartley B, Saeed P, Gajdosova E, van den Brekel MW, Balm AJM, Hol MLF, van Jaarsveld S, Kremer LCM, Ronckers CM, Mandeville HC, Pieters BR, Gaze MN, Davila Fajardo R, Strackee SD, Dunaway D, Smeele LE, Chisholm JC, Caron HN, Grootenhuis MA, and Merks JHM
- Subjects
- Adolescent, Child, Cross-Sectional Studies, Female, Humans, Male, Quality of Life, Surveys and Questionnaires, Cancer Survivors psychology, Head and Neck Neoplasms psychology, Rhabdomyosarcoma psychology
- Abstract
Background: Head and neck rhabdomyosarcoma (HNRMS) survivors are at risk to develop adverse events (AEs). The impact of these AEs on psychosocial well-being is unclear. We aimed to assess psychosocial well-being of HNRMS survivors and examine whether psychosocial outcomes were associated with burden of therapy., Procedure: Sixty-five HNRMS survivors (median follow-up: 11.5 years), treated in the Netherlands and the United Kingdom between 1990 and 2010 and alive ≥2 years after treatment visited the outpatient multidisciplinary follow-up clinic once, in which AEs were scored based on a predefined list according to the Common Terminology Criteria for Adverse Events. Survivors were asked to complete questionnaires on health-related quality of life (HRQoL; PedsQL and YQOL-FD), self-perception (KIDSCREEN), and satisfaction with appearances (SWA). HRQoL and self-perception scores were compared with reference values, and the correlation between physician-assessed AEs and psychosocial well-being was assessed., Results: HNRMS survivors showed significantly lower scores on PedsQL school/work domain (P ≤ 0.01, P = 0.02, respectively), YQOL-FD domains negative self-image and positive consequences (P ≤ 0.01, P = 0.04, respectively) compared with norm data; scores on negative consequences domain were significantly higher (P = 0.03). Over 50% of survivors negatively rated their appearances on three or more items. Burden of AEs was not associated with generic HRQoL and self-perception scores, but was associated with disease-specific QoL (YQOL-FD)., Conclusion: In general, HRQoL in HNRMS survivors was comparable to reference groups; however, survivors did report disease-specific consequences. We therefore recommend including specific questionnaires related to difficulties with facial appearance in a systematic monitoring program to determine the necessity for tailored care., (© 2018 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
42. Melanotic neuroectodermal tumour of infancy: A case report and differential diagnosis.
- Author
-
Tan AP, Jacques TS, Mankad K, James G, Jeelani O, Slater O, and D'Arco F
- Subjects
- Diagnosis, Differential, Humans, Infant, Meningocele etiology, Meningocele therapy, Neuroectodermal Tumor, Melanotic pathology, Neuroectodermal Tumor, Melanotic surgery, Postoperative Complications therapy, Skull Neoplasms pathology, Skull Neoplasms surgery, Temporal Bone pathology, Temporal Bone surgery, Neuroectodermal Tumor, Melanotic diagnostic imaging, Skull Neoplasms diagnostic imaging, Temporal Bone diagnostic imaging
- Abstract
Melanotic neuroectodermal tumour of infancy is an uncommon pigmented neoplasm of neural crest origin. It was first described in 1918 by Krompecher, known as congenital melanocarcinoma at that time. Although it is generally agreed upon that it is a benign entity, it is locally aggressive and has a significant recurrent risk, reported to be between 10-15%. There have also been prior reports of malignant behaviour in these tumours, although extremely rare. The majority of cases of this tumour (about 70%) arise from the maxilla and its occurrence in the cranial vault represents approximately 15.6% of cases. We describe a rare case of melanotic neuroectodermal tumour of infancy, with simultaneous involvement of the cranial vault and petrous temporal bone, in a four-month-old child, complicated by post-surgical pseudo-meningocele. This case illustrates the diagnostic dilemma in differentiating reactive osseous sclerosis from direct tumour infiltration, both of which can occur in the context of melanotic neuroectodermal tumour of infancy. The discussion places emphasis on differential diagnoses and useful radiological features to assist in clinching the diagnosis of melanotic neuroectodermal tumour of infancy.
- Published
- 2018
- Full Text
- View/download PDF
43. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants.
- Author
-
Wegert J, Vokuhl C, Collord G, Del Castillo Velasco-Herrera M, Farndon SJ, Guzzo C, Jorgensen M, Anderson J, Slater O, Duncan C, Bausenwein S, Streitenberger H, Ziegler B, Furtwängler R, Graf N, Stratton MR, Campbell PJ, Jones DT, Koelsche C, Pfister SM, Mifsud W, Sebire N, Sparber-Sauer M, Koscielniak E, Rosenwald A, Gessler M, and Behjati S
- Subjects
- Female, Gene Rearrangement, Humans, Infant, Infant, Newborn, Male, Fibrosarcoma genetics, Genes, erbB-1, Kidney Neoplasms genetics, Nephroma, Mesoblastic genetics, Proto-Oncogene Proteins B-raf genetics
- Abstract
Soft tissue tumors of infancy encompass an overlapping spectrum of diseases that pose unique diagnostic and clinical challenges. We studied genomes and transcriptomes of cryptogenic congenital mesoblastic nephroma (CMN), and extended our findings to five anatomically or histologically related soft tissue tumors: infantile fibrosarcoma (IFS), nephroblastomatosis, Wilms tumor, malignant rhabdoid tumor, and clear cell sarcoma of the kidney. A key finding is recurrent mutation of EGFR in CMN by internal tandem duplication of the kinase domain, thus delineating CMN from other childhood renal tumors. Furthermore, we identify BRAF intragenic rearrangements in CMN and IFS. Collectively these findings reveal novel diagnostic markers and therapeutic strategies and highlight a prominent role of isolated intragenic rearrangements as drivers of infant tumors.
- Published
- 2018
- Full Text
- View/download PDF
44. Anterior Mediastinal Mass in a Child-Known but Rare Entity.
- Author
-
Muthialu N, McHugh K, and Slater O
- Abstract
Thymomas are exceedingly rare tumours of the anterior mediastinum in children. An early awareness helps timely surgical intervention. Thymomas can occasionally be extremely aggressive. The loss of contour on chest X-Ray, to be confirmed as a large anterior mediastinal mass at computerised tomography, serves identification of a typical bilobed thymic tumour., Competing Interests: Compliance with Ethical StandardsThe authors declare that they have no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
45. Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience.
- Author
-
Unni MNM, Elfeky R, Rao K, Nademi Z, Chiesa R, Amrolia P, Skinner R, Slater O, Worth A, Flood T, Abinun M, Hambleton S, Qasim W, Gaspar HB, Cant AJ, Gennery AR, Veys P, and Slatter MA
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Incidence, Male, Neoplasms etiology, Retrospective Studies, United Kingdom, Hematopoietic Stem Cell Transplantation, Immunologic Deficiency Syndromes therapy, Neoplasms epidemiology
- Published
- 2018
- Full Text
- View/download PDF
46. Facial asymmetry in head and neck rhabdomyosarcoma survivors.
- Author
-
Schoot RA, Hol MLF, Merks JHM, Suttie M, Slater O, van Lennep M, Hopman SMJ, Dunaway D, Syme-Grant J, Smeele LE, Zwinderman KH, Caron HN, and Hammond P
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Head and Neck Neoplasms pathology, Humans, Male, Rhabdomyosarcoma pathology, Facial Asymmetry etiology, Facial Asymmetry pathology, Head and Neck Neoplasms radiotherapy, Imaging, Three-Dimensional, Rhabdomyosarcoma radiotherapy, Survivors
- Abstract
Introduction: Radiotherapy is essential for achieving and maintaining local control in head and neck rhabdomyosarcoma (HNRMS) patients. However, radiotherapy may cause outgrowth disturbances of facial bone and soft tissue, resulting in facial asymmetry. The aim of this study was to develop a method to visualize and measure facial asymmetry in HNRMS survivors using three-dimensional (3D) imaging techniques., Methods: Facial deformity was evaluated in a multidisciplinary clinical assessment of 75 HNRMS survivors, treated with external beam radiotherapy (EBRT, n = 26) or Ablative surgery, MOulage brachytherapy, and REconstruction (AMORE, n = 49). Individual facial asymmetry was measured using 3D photogrammetry and expressed in a raw asymmetry index and a normalized sex-age-ethnicity-matched asymmetry signature weight. Facial asymmetry was also compared between British and Dutch controls and between survivors and their matched controls., Results: Facial asymmetry was more pronounced with increasing age (P < 0.01) in British controls compared with Dutch controls (P = 0.04). Survivors developed more facial asymmetry than matched controls (P < 0.001). The clinical assessment of facial deformity correlated with the raw asymmetry index (r = 0.60, P < 0.001)., Discussion: 3D imaging can be used for objective measurement of facial asymmetry in HNRMS survivors. The raw asymmetry index correlated with a clinical assessment of facial deformity. Comparisons between treatment groups seemed inappropriate given the differences in facial asymmetry between British and Dutch controls. In future studies, pretreatment images could act as matched controls for posttreatment evaluation., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
47. Initial response with paradoxical deterioration following bevacizumab for cerebral radiation necrosis.
- Author
-
Tan R, Michalski A, Saran F, Mankad K, and Slater O
- Subjects
- Adolescent, Female, Humans, Bevacizumab administration & dosage, Brain Neoplasms therapy, Dose Fractionation, Radiation, Neuroectodermal Tumors, Primitive therapy, Radiation Injuries drug therapy
- Published
- 2017
- Full Text
- View/download PDF
48. MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
- Author
-
Kinsler VA, O'Hare P, Jacques T, Hargrave D, and Slater O
- Subjects
- Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms pathology, Child, Preschool, Female, Humans, Infant, Male, Melanoma genetics, Melanoma pathology, Prognosis, Protein Kinase Inhibitors therapeutic use, Skin Neoplasms genetics, Skin Neoplasms pathology, Central Nervous System Neoplasms drug therapy, GTP Phosphohydrolases genetics, MAP Kinase Kinase 1 antagonists & inhibitors, Melanoma drug therapy, Membrane Proteins genetics, Mutation genetics, Pyridones therapeutic use, Pyrimidinones therapeutic use, Skin Neoplasms drug therapy
- Abstract
Background: Primary melanoma of the CNS in children is extremely rare, and usually linked to congenital melanocytic naevus syndrome, caused by mosaicism for oncogenic NRAS mutations. Outcome is fatal in all cases. Data from murine and in vitro studies suggest that MEK inhibition is a possible therapeutic option., Methods: Four children with NRAS-mutated CNS melanoma were treated with Trametinib on a compassionate basis., Results: All four had an improvement in symptoms and objectively in signs. These varied from mild improvement for 1 month, to a sustained symptom-free period of 9 months in one case. In all cases there was eventual disease progression through treatment, followed by rapid death after discontinuation. There were no clinically-significant side effects., Conclusions: Trametinib is the first therapy to show any objective or measurable effect in NRAS-mutated primary CNS melanoma, with few side effects in this small series. The role of this therapy should be explored further in this rare paediatric tumour.
- Published
- 2017
- Full Text
- View/download PDF
49. An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre.
- Author
-
Fosbury E, Szychot E, Slater O, Mathias M, and Sibson K
- Subjects
- Child, Child, Preschool, Female, Follow-Up Studies, Hemorrhage epidemiology, Humans, Incidence, Infant, Male, Prognosis, Retrospective Studies, Tertiary Care Centers, United Kingdom epidemiology, von Willebrand Diseases diagnosis, Kidney Neoplasms physiopathology, Wilms Tumor physiopathology, von Willebrand Diseases epidemiology
- Abstract
Wilms tumour (WT) is the commonest primary malignant renal tumour of childhood. Acquired von Willebrand syndrome (avWS) is a well-described paraneoplastic phenomenon, but it is uncommon and may not be detected until clinically significant bleeding is encountered during interventional procedures. Previous studies on small cohorts of patients have determined an incidence of between 4 and 8%. We have performed a retrospective study on cases of WT presenting over an 11.5-year period to a paediatric haematology/oncology unit in a tertiary referral centre to review the incidence of avWS, bleeding phenotype, management, and response to treatment of the primary pathology., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
50. Cushing syndrome in a child due to pro-opiomelanocortin (POMC) secretion from a yolk sac tumor.
- Author
-
Gevers EF, Meredith S, Shah P, Torpiano J, Peters C, Sebire NJ, Slater O, White A, and Dattani MT
- Subjects
- Abdominal Neoplasms blood, Abdominal Neoplasms metabolism, Adrenocorticotropic Hormone blood, Child, Preschool, Cushing Syndrome blood, Endodermal Sinus Tumor blood, Endodermal Sinus Tumor metabolism, Female, Humans, Abdominal Neoplasms complications, Cushing Syndrome etiology, Endodermal Sinus Tumor complications, Pro-Opiomelanocortin metabolism
- Abstract
Context: Pituitary microadenomas and adrenal tumours are the most common causes for endogenous Cushing syndrome (CS) in children., Case Description: We describe a two-year old girl with Cushing syndrome due to ectopic pro-opiomelanocortin (POMC) production from an abdominal yolk sac tumor. Cortisol concentrations were elevated but adrenocorticotropic hormone (ACTH) concentrations were equivocal. The use of antibodies specifically detecting ACTH precursors revealed that plasma ACTH precursors were elevated. Additionally, an ACTH assay with a low cross-reactivity for precursors showed low concentrations of ACTH. Immunohistochemistry suggested POMC but not ACTH production by the tumour., Conclusion: We describe a yolk sac tumour as a novel source of ectopic POMC production leading to CS in a young girl., (© 2017 European Society of Endocrinology.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.